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In glaucoma, harmful intraocular pressure often contributes to retinal ganglion cell death. It is not clear, however, if
intraocular pressure directly insults the retinal ganglion cell axon, the soma, or both. The pathways that mediate
pressure-induced retinal ganglion cell death are poorly defined, and no molecules are known to be required. DBA/2J
mice deficient in the proapoptotic molecule BCL2-associated X protein (BAX) were used to investigate the roles of BAX-
mediated cell death pathways in glaucoma. Both Bax
+/  and Bax
 /  mice were protected from retinal ganglion cell
death. In contrast, axonal degeneration was not prevented in either Bax
+/ or Bax
 / mice. While BAX deficiency did not
prevent axonal degeneration, it did slow axonal loss. Additionally, we compared the effects of BAX deficiency on the
glaucoma to its effects on retinal ganglion cell death due to two insults that are proposed to participate in glaucoma.
As in the glaucoma, BAX deficiency protected retinal ganglion cells after axon injury by optic nerve crush. However, it
did not protect retinal ganglion cells from N-methyl-D-aspartate (NMDA)-induced excitotoxicity. BAX is required for
retinal ganglion cell death in an inherited glaucoma; however, it is not required for retinal ganglion cell axon
degeneration. This indicates that distinct somal and axonal degeneration pathways are active in this glaucoma. Finally,
our data support a role for optic nerve injury but not for NMDA receptor-mediated excitotoxicity in this glaucoma.
These findings indicate a need to understand axon-specific degeneration pathways in glaucoma, and they suggest that
distinct somal and axonal degeneration pathways may need to be targeted to save vision.
Citation: Libby RT, Li Y, Savinova OV, Barter J, Smith RS, et al. (2005) Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS Genet 1(1): e4.
Introduction
Glaucoma is a common blinding disease affecting approx-
imately 70 million people worldwide [1]. Glaucoma is often
associated with elevated intraocular pressure (IOP). IOP
elevation and glaucoma are typically spontaneous, progres-
sive, idiopathic processes and are most common in the elderly
[2]. Although IOP-lowering treatments slow the development
and progression of glaucoma in many patients [3,4], it is not
always possible to reduce IOP to a ‘‘safe’’ level [5]. Vision loss
in glaucoma is the result of retinal ganglion cell (RGC) death
with accompanying optic nerve atrophy, so glaucoma is a
neuropathy. IOP elevation is not detected in a signiﬁcant
subset of glaucomas [6,7]. Thus, the unifying characteristic of
glaucoma is RGC death. While there are several hypotheses as
to why elevated IOP kills RGCs, both the precise biochemical
cascades that are triggered within RGCs and the nature of the
proximal insult(s) that trigger these cascades remain super-
ﬁcially deﬁned [8]. No treatments that directly protect the
neurons are in routine clinical use.
The complex nature of glaucoma makes studies of its
pathogenesis difﬁcult [9]. Consequently, no speciﬁc molecules
have been shown to be essential for RGC death in glaucoma.
Standard glaucoma-relevant models include direct RGC
trauma, direct optic nerve trauma, and suddenly induced
IOP elevation [10–18]. Although these induced models have
provided valuable information, the relevance of speciﬁc
damaging mechanisms may differ signiﬁcantly between
spontaneous and experimentally induced glaucomas. Thus,
studies using inherited glaucoma models are also necessary.
Apoptosis is known to contribute to RGC death following
experimentally induced insults including axotomy and IOP
elevation (e.g., [19,20]), and there is also some evidence that
apoptosis is involved in human glaucoma [21,22]. A number
of molecules that are known to affect apoptosis are reported
to be important regulators of RGC death after various
induced insults. These include X-linked inhibitor of apoptosis
protein (XIAP) [23–25], p38 [26], several caspases [27–30], the
B-cell lymphoma/leukemia 2 (BCL2) family of apoptotic
regulators [20,31–34], and members of the c-Jun N-terminal
kinase (JNK) [35,36] and tumor necrosis factor (TNF) [35,37]
signaling pathways. One of these molecules, BCL2-associated
X protein (BAX; a proapoptotic member of the BCL2 family),
has a major role in mitochondrial-mediated apoptosis in
different neuronal cell types [38,39]. In mice, BAX deﬁciency
increases the number of RGCs in the adult retina by 220% by
allowing more RGCs to survive during development [39].
Genetic or induced BAX deﬁciency is also known to prevent
RGC apoptosis after optic nerve crush and axotomy
[13,18,40]. Thus, BAX-mediated apoptosis is clearly an
important mechanism of stress-induced RGC death. Whether
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either experimentally induced or inherited glaucomas is not
known.
Understanding the pathophysiologic mechanisms of RGC
death in glaucoma and the genetic susceptibility factors
contributing to this process is important for the development
of effective and individualized treatments. Here, we use the
genetically uniform DBA/2J mouse model of glaucoma [41–
43] to assess the importance of mitochondrially mediated
apoptosis in an inherited glaucoma. Importantly, we show
that in this model of inherited glaucoma there are distinct
RGC death and axonal degeneration pathways. The RGC
death pathway is BAX dependent and, therefore, apoptotic.
The axonal degeneration pathway is BAX independent.
Finally, our data suggest that reducing BAX levels in the
retina may retard the rate of vision loss in glaucoma.
Results
Apoptosis Is Physiologically Relevant for RGC Death in an
Inherited Glaucoma
To determine if RGC apoptosis has a signiﬁcant role in an
inherited glaucoma, we assessed DNA fragmentation, chro-
matin condensation, and cellular ultrastructure in glaucom-
atous DBA/2J retinas. We identiﬁed hallmarks of apoptosis
including the presence of TUNEL-positive cells that peaked
between 10 and 13 mo of age (the period when the majority of
RGC death occurs in this model) (Figure 1). These results
conﬁrm earlier suggestive studies that apoptotic pathways are
important mediators of RGC death in spontaneous glaucoma
[19–22].
Homozygous but Not Heterozygous BAX Deficiency Alters
RGC Number
To test the role of BAX in glaucomatous RGC death, we
extensively backcrossed a previously characterized null allele
of Bax (Bax
tm1Sjk) [44] onto the inbred DBA/2J background. In
mammals, approximately twice as many RGCs are produced
during retinal development than survive into adulthood [45–
47]. As expected from previous studies of retinal develop-
ment on a different genetic background [39], complete BAX
deﬁciency increased the number of RGC-layer somata in
adult DBA/2J mice by 220% (average cell number per 403
ﬁeld 6 standard error of the mean [SEM], number of retinas
analyzed: Bax
+/+, 199 6 5.6, n =7 ;Bax
 / , 437 6 15.3, n = 8).
In agreement with this, Bax
 /  mice had 217% more RGC
axons than Bax
+/+ mice (Bax
+/+, 50,504 6 1,988, n =8 ;Bax
 /
 , 108,907 6 10,322, n =4 ;p , 0.001). Reﬂecting the
increased number of RGC axons and the proportional
increase in glial cell types [48], the cross sectional area of
Bax
 /  optic nerves was signiﬁcantly increased (average 6
SEM, number of optic nerves measured: Bax
+/+, 0.157 6
0.005 mm
2, n = 13; Bax
 / , 0.278 6 0.008 mm
2, n = 16; p ,
0.001). In heterozygous Bax
+/  mice, RGC number (average
per 403 ﬁeld 6 SEM, 212 6 14.0, n =5) and the optic nerve
area (0.171 6 0.007 mm
2, n = 13) was not different from
Bax
+/+ mice (p = 0.352 and p = 0.107, respectively). Thus,
heterozygous levels of BAX are sufﬁcient for death of the
normal numbers of RGCs during retinal development.
BAX Ablation Preserves RGC Numbers but Does Not
Prevent RGC Axonal Degeneration in Glaucoma
To determine the role of BAX in glaucomatous RGC death,
we assessed the effects of BAX deﬁciency on RGC survival and
on RGC axonal degeneration (see Materials and Methods).
Our results show that BAX is not required for RGC axon
degeneration. Bax
 /  mice developed severe optic nerve
damage, including essentially complete loss of axons (Figure
2). In contrast, our experiments show that BAX is required
for RGC death in glaucoma (Figure 3). Despite severe axonal
degeneration, the numbers of cell bodies in the RGC layer of
Bax
 /  mice were normal. As a stringent test of this
observation, we counted RGC-layer cell bodies in the retinas
of mice with severe (  95% loss) axon degeneration. The
number of RGC cell bodies was normal in Bax
 /  mice with
more than 95% axon loss (Figure 3). Importantly, Bax
+/ mice
were also protected against glaucomatous RGC death. Bax
+/ 
mice with an axon loss of 95% or more also had substantially
increased survival of RGC cell bodies as compared to Bax
+/+
controls (Figure 3E). Thus, RGC death and axonal degener-
ation are clearly distinguished in these experiments.
Other Proapoptotic Molecules Do Not Compensate for
BAX Deficiency
In some neuronal cell types, BAX deﬁciency delays but does
not prevent apoptosis [49]. This is because other proapop-
totic molecules (e.g., another BCL2 family member, BAK)
mediate cell death in the BAX-deﬁcient neurons [50]. To test
this possibility in the DBA/2J model, we aged Bax
 /  mice to18
mo. As expected in a complex age-related disease, the severity
of glaucomatous damage varies between individual DBA/2J
eyes at any age. Nevertheless, by 12 mo of age, the majority of
eyes have severe optic nerve damage (see below). Therefore,
18 mo of age is 6 mo after the majority of eyes have severe
axon loss. Despite this extensive axonal degeneration, there
was no obvious reduction in RGC numbers in any of the 18-
mo-old Bax
 / eyes (Figure 3E). This result indicates that other
molecules do not substitute for BAX and that BAX is essential
for RGC apoptosis in DBA/2J inherited glaucoma.
Homozygous BAX Deficiency Alters IOP
DBA/2J mice develop a form of pigmentary glaucoma that
is secondary to a progressive iris disease. Iris pigment and cell
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Synopsis
Glaucoma is a group of diseases whose unifying characteristic is
death of nerve cells (retinal ganglion cells) that connect the eye to
the brain. Glaucoma is often associated with a harmfully high
pressure inside the eye (intraocular pressure) contributing to nerve
cell death. Various treatments are used to lower eye pressure, but
currently no commonly used treatments directly protect the nerve
cells. DBA/2J mice develop elevated eye pressure with age, and this
pressure kills retinal nerve cells. The authors use this mouse model
to investigate how these nerve cells die in glaucoma. They show
that there are distinct degeneration pathways activated in different
parts of the retinal nerve cells. They found that the biochemical
pathway in the nerve cell body, which resides in the retina, requires
a molecule called BAX (BCL2-associated X protein). In contrast,
pathways in the part of the cell (axon) that connects the cell body to
the brain do not require BAX. Because degeneration pathways in the
cell body and of the axon also may be molecularly different in
human glaucoma, it will be important to consider them all when
designing therapies. Their data also suggest that the BAX gene is a
candidate to modulate glaucoma susceptibility.Figure 1. Dying RGCs Have Characteristic Features of Apoptosis
(A–C) A double-labeling assay that identifies fragmented DNA using fluorescently labeled dUTP (A) and detects chromatin condensation by binding of
the dye YOYO-1 (B) was used to assess the presence of these hallmarks of apoptosis in glaucomatous DBA/2J eyes at 10–11 mo of age (a time when
many RGCs die). A cell in the retinal ganglion cell layer (GCL, arrowhead) has both of these features of apoptosis as indicated by double labeling (C). INL,
inner nuclear layer.
(D–F) Electron microscopy provided further evidence for apoptosis. (D) An example of a healthy RGC. (E) Chromatin condensation (a hallmark of
apoptosis) along the inner surface of the nuclear envelope in a ganglion cell (arrows). The internal limiting membrane of the retina is indicated by
arrowheads. (F) An apoptotic body in the ganglion cell layer (arrows) containing a nuclear fragment with prominent condensed chromatin (asterisk) and
other cell remnants.
(G) A TUNEL assay (see Materials and Methods) was used to assess the prevalence of cell death at different ages. TUNEL labeling was not detected at 7
mo (an age prior to glaucomatous cell death) and peaked at 10–13 mo, when most RGCs die. No TUNEL-positive cells were detected in
nonglaucomatous, age-matched control mice. These results support an important role of apoptosis in RGC death in spontaneous glaucoma. Scale bar, 1
lm.
DOI: 10.1371/journal.pgen.0010004.g001
PLoS Genetics | www.plosgenetics.org July 2005 | Volume 1 | Issue 1 | e4 0019
Bax in Glaucoma Susceptibilitydebris enter the ocular drainage structures, resulting in
subsequent IOP elevation [41,42]. The increase in IOP
induces RGC death. Manipulations that alleviate the iris
disease and prevent IOP elevation also prevent RGC death in
this strain [41]. To assess the effects of BAX deﬁciency, the
clinical phenotypes and IOP proﬁles of mice of each Bax
genotype were carefully examined at multiple ages.
Periodic assessment of the progression of iris abnormalities
by slit-lamp examinations (approximately every 2 mo
between 3 and 12 mo of age) revealed no differences between
mice of each Bax genotype. Histologic analysis conﬁrmed
these observations (unpublished data). Thus, BAX-mediated
processes are not necessary for the progression of the iris
disease.
Although iris damage was similar in mice of all three
genotypes, Bax genotype did have an effect on IOP. The peak
period of IOP elevation in DBA/2J mice is from 9 to 12 mo of
age, with the IOP distribution clearly shifting upward
between 8 and 9 mo. We monitored IOP at key ages (9,
10.5, and 12 mo). Surprisingly, Bax
 /  mice tended to have
lower IOP than either Bax
+/ or Bax
+/+ mice at 9 mo, and the
difference was statistically signiﬁcant at 10.5 mo of age
(Figure 4). In contrast, the IOPs of Bax
+/  and Bax
+/+ mice
were not different. Because of the lower IOP in Bax
 /  mice,
we analyzed IOP in 4-mo-old mice of each genotype and
found no differences (average 6 SEM, number of eyes
examined: Bax
+/+, 13.54 6 0.45 mm Hg, n = 22; Bax
+/ ,
13.77 6 0.33, n = 22; Bax
 /  13.46 6 0.34, n = 20; p . 0.5).
Figure 2. BAX Is Not Required for Glaucomatous Optic Nerve
Degeneration
To assess the effects of Bax deficiency on optic nerve degeneration, we
analyzed PPD-stained optic nerve cross sections from Bax
+/+ and Bax
 / 
mice (n . 49 for each genotype; see Materials and Methods).
(A and B) Before the DBA/2J glaucoma damages RGCs, the optic nerves
of both Bax
+/+ (A) and Bax
 /  mice (B) had a normal organization. The
axons appeared healthy with a clear axoplasm and darkly stained myelin
sheath.
(C and D) BAX deficiency did not prevent glaucomatous optic nerve
damage. Severe degeneration involving extensive to complete axon loss
and scarring occurred in both Bax
+/+ (C) and Bax
 /  mice (D). The
majority of mice of both genotypes had this severe degree of damage by
12 mo of age. These experiments show that BAX is not required for
glaucomatous axon degeneration. Scale bar, 50 lm.
DOI: 10.1371/journal.pgen.0010004.g002
Figure 3. Bax Deficiency Prevents Glaucomatous RGC Death
To determine the effects of BAX deficiency on RGC death in glaucoma,
we analyzed RGC layer cells at stages with and without glaucomatous
optic nerve damage (see Materials and Methods). All shown images are
from a similar region of the superior, peripheral retina.
(A and B) In both Bax
+/+ (A) and Bax
 /  (B) mice without glaucomatous
optic nerve damage, the retinas appear healthy. The retinas of both
genotypes are similar except that Bax
 /  mice have extra RGCs (since
BAX is important in normal developmental RGC death [39]).
(C and D) In contrast, an obvious difference was evident between the
retinas of Bax
+/+ and Bax
 /  mice that had all suffered severe
glaucomatous damage with 95% or more axon degeneration. As
expected, for Bax
+/+ retinas (C) from eyes with 95% or more optic nerve
axon loss, there was a noticeable decrease in RGC layer cells (compare [C]
to [A]). In contrast, retinas from Bax
 /  mice with correspondingly
damaged optic nerves (D) had suffered no obvious loss of RGC layer cells
(compare [D] to [B]). This suggests that BAX is required for RGC death in
DBA/2J glaucoma. As is well established for both RGCs and other
neurons, Bax
 /  RGCs that survive without axons have a shrunken
morphology [38,82]. This is clearly evident in the Bax
 /  glaucomatous
mice (D).
(E) RGC layer cell counts for eyes with 95% or more axon degeneration
confirmed that BAX is necessary for RGC death in this glaucoma. To allow
comparison between genotypes, the percent of surviving cells is shown
(% soma in mice with 95% or more axon loss compared to mice of the
same genotype without glaucomatous damage). At 12 mo of age, Bax
+/+
mice had 61.4% 6 3.8% of their RGC layer cells remaining, Bax
 /  mice
had no appreciable cell loss (101% 6 5.3%). The RGC layer cells of Bax
+/ 
mice were also protected (89.2% 6 5.7%). The p values comparing
differences in cell counts between nonglaucomatous and very severely
glaucomatous (  95% axon loss) eyes of the same genotype were:
Bax
+/+, p , 0.001; Bax
+/ , p = 0.207; Bax
 / , p = 0.426. No cell loss was
seen in Bax
 / mice even out to 18 mo (94.8% 6 4.4% cells surviving, p¼
0.524 compared to nonglaucomatous Bax
 /  mice). These findings show
that BAX gene dosage has an important effect on the susceptibility of
RGCs to glaucomatous death. Scale bar, 50 lm.
DOI: 10.1371/journal.pgen.0010004.g003
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Bax in Glaucoma SusceptibilityThis result indicates that BAX deﬁciency does not alter
baseline IOP but does have an effect as the IOP increases to
glaucomatous levels in older mice.
The lower IOP insult in Bax
 /  mice does not account for
the survival of their RGCs. This conclusion is supported by
the normal RGC numbers remaining in Bax
+/  mice with
indistinguishable IOP from Bax
+/+ mice. Previous studies
have shown that BAX deﬁciency allows RGC survival
following axotomy or optic nerve crush [13]. By contrast,
even when neuroprotective treatments are administered, only
a small number RGCs survive in the short term (4–6 wk) in
Bax
+/+ mice exposed to severe axon trauma [51,52]. Thus,
there is no reasonable explanation for the ﬁnding of
prolonged survival of RGCs that have no axons other than
that BAX is a necessary RGC-intrinsic molecule for apoptosis
in this glaucoma model.
Bax Deficiency Delays Axon Degeneration
Although we have shown that axon degeneration is not
dependent upon BAX, our results clearly identify BAX as an
endogenous susceptibility factor for both RGC death and
axonal degeneration in DBA/2J glaucoma. As discussed above,
complete or partial BAX deﬁciency had a profound rescuing
effect on RGC cell bodies. Importantly, decreasing functional
Bax gene dosage also decreased susceptibility to glaucoma by
delaying the progression of axon damage (Figure 5). At 10.5
mo of age, the majority of Bax
+/+ mice had moderate or
severe optic nerve damage (see Materials and Methods), with
only 20% being mildly affected. In contrast, 53% of Bax
 / 
and 44% of Bax
+/  mice were only mildly affected at 10.5 mo
of age. At 12.0 mo of age, the distribution of optic nerve
damage was indistinguishable among mice of the three Bax
genotypes (Figure 5). Since mice of each Bax genotype were
littermates that were housed in the same cages throughout
aging, these results provide compelling evidence that de-
creasing BAX levels delays optic nerve damage.
The delay of optic nerve damage in Bax
+/  mice (note:
Bax
+/  mice had similar IOP insults to Bax
+/+ mice) suggests
that partially decreasing BAX levels in RGCs protects RGC
axons. However, since complete BAX deﬁciency limited IOP
elevation, a further protective effect of BAX deﬁciency by
lowering IOP is also possible and may explain the trend
toward greater axonal protection in Bax
 /  mice. Thus, it is
possible that either low-expressing or low-activity alleles of
BAX may affect glaucoma susceptibility both by limiting and/
or delaying IOP elevation and by directly protecting RGCs
from damaging effects of harmfully high IOP.
An Integrated Approach Supports a Role of Direct Optic
Nerve Injury in Glaucoma
Comparing the speciﬁc pathways active in glaucomatous
RGC death to the pathways induced by acute, experimental
manipulations can provide information about the initial
insult(s) to RGCs in glaucoma. N-methyl-D-aspartate (NMDA)
receptor-mediated excitotoxic injury and direct axon injury
are two insults that have been proposed to kill RGCs in
glaucoma. Acute experimental procedures can be used to
mimic these insults. Intraocular NMDA injection is used to
mimic excitotoxic RGC insult, and controlled optic nerve
crush is used to mimic a direct axon insult [53,54]. To assess
the likely roles of these insults in a spontaneous glaucoma, we
subjected preglaucomatous DBA/2J mice of differing Bax
genotypes to these procedures. This allowed direct compar-
ison of RGC death induced by these distinct excitotoxic and
axonal insults to the naturally progressing glaucoma (Figure
6) in a single genetic context. Bax genotype had absolutely no
Figure 4. Complete Bax Deficiency Has a Protective Effect against IOP
Elevation
To assess the possibility that Bax deficiency may delay axon
degeneration by lessening the glaucomatous insult to which RGCs are
exposed, we analyzed IOP at key ages of IOP elevation. (A) The average
IOP for each genotype (6 SEM) and (B) the actual IOP values recorded.
Bax deficiency did not prevent IOP elevation. At both 9 mo and 10.5
mo, the average IOP of both Bax
+/  and Bax
 /  mice was significantly
elevated compared to preglaucomatous DBA/2J mice (p , 0.001). The
width of the horizontal line (black in [A], gray in [B]) represents the
mean IOP 6 SEM of a group of wild-type preglaucomatous DBA/2J
mice that were 3 mo old. The degree of IOP elevation, however, was
altered in Bax
 /  mice. In both 9- and 10.5-mo-old Bax
 /  mice, the
average IOP was less than that of Bax
+/+ and Bax
+/  mice. This reduction
in IOP elevation was significant at 10.5 mo (p , 0.01). The IOP of Bax
+/ 
mice did not differ from wild type at either 9 or 10.5 mo (p . 0.82). By
12 mo, there was no difference in IOP between mice of any genotype
(p . 0.25).
DOI: 10.1371/journal.pgen.0010004.g004
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Bax in Glaucoma Susceptibilityeffect on RGC death initiated by intraocular injection of the
excitotoxin NMDA. In contrast, the RGCs of both Bax
+/  and
Bax
 /  mice were profoundly protected against optic nerve
crush. Since RGC death in the DBA/2J glaucoma is also BAX
dependent, these data support a role for axon injury, but not
for excitotoxicity (at least through the NMDA receptor) in
this glaucomatous RGC death.
Discussion
BAX-Mediated Apoptosis Is Important in an Inherited
Glaucoma
Our ﬁndings provide important new information about
RGC injury and death in glaucoma. BAX deﬁciency com-
pletely prevents RGC death in DBA/2J mice. These results
conclusively demonstrate that apoptosis plays a pivotal role
in this inherited model of glaucoma. BAX is the ﬁrst molecule
shown to be completely necessary for RGC death in any
glaucoma. Considering the protection we demonstrate in this
mouse model, it is worth assessing BAX pathways as
important targets for new treatments in human glaucoma.
Distinct Pathways Mediate RGC Death and Axonal
Degeneration in Glaucoma
Intrinsic axonal degeneration pathways have recently been
identiﬁed [55,56]. The molecular components of these path-
ways appear to be distinct from those active in classical somal
apoptosis [57,58]. Thus, the different compartments of a
neuron can degenerate by different molecular processes. In
glaucoma, it is not clear whether the same or different
degeneration pathway(s) are activated in the cell body and
axon. Our study demonstrates that BAX is required for RGC
death but not for RGC axonal degeneration in DBA/2J
glaucoma. This indicates that the axonal degeneration path-
way is distinct from apoptosis in this inherited glaucoma. Our
ﬁndings clearly demonstrate that axon degeneration is not a
consequence of RGC death, since severe axon degeneration
occurred in Bax
 /  mice without RGC death. It is not yet clear
whether the RGC apoptosis and axonal degeneration path-
ways have some common features or are completely distinct.
However, for the design of therapeutic strategies for human
glaucoma, our studies suggest that both apoptotic and axonal
degeneration pathways should be considered.
Alternative Glaucoma Hypotheses
The initial RGC compartments that are insulted in
glaucoma, as well as the nature of the damaging insults that
induce degeneration, are not completely clear. In the
excitotoxic hypothesis of glaucoma, elevated IOP leads to
Figure 5. Glaucomatous Optic Nerve Degeneration Is Delayed in Bax-
Deficient Mice
BAX deficiency did not prevent glaucomatous axon degeneration.
Nevertheless, the beneficial effect on RGC survival raised the possibility
that it may have a protective effect on the axon and delay optic nerve
damage. To assess this, three investigators masked to genotype
determined the severity of optic nerve damage for mice of each Bax
genotype at each age (n = 49–71 per genotype at each age; see Materials
and Methods). At 10.5 mo, both Bax
+/  and Bax
 /  mice had significantly
less optic nerve damage than Bax
+/+ mice. Mild damage was evident in
53% of Bax
 /  and 44% of Bax
+/  optic nerves, compared to only 20% of
Bax
+/+ (p , 0.001 for both Bax
+/  and Bax
 /  compared to Bax
+/+; Chi
2
test). With disease progression to 12 mo of age, the distribution of optic
nerve damage became indistinguishable among mice of different Bax
genotypes (p . 0.10). Quantitative assessment of a random subset of
nerves assigned each damage level (more than eight of each)
demonstrates that the number of axons that remain in optic nerves
having each damage level are clearly different (see Materials and
Methods).
DOI: 10.1371/journal.pgen.0010004.g005
Figure 6. Mechanical Axon Insult, but Not Excitotoxicity, Induces BAX-
Dependent RGC Death
To help distinguish between the likely roles of mechanical axon insult
and excitotoxicity in cell death induction in spontaneous glaucoma, we
subjected preglaucomatous DBA/2J mice of each Bax genotype to either
controlled optic nerve crush or NMDA-mediated excitotoxicity. For
controlled crush and NMDA, the percent RGC survival in the manipulated
eye compared to the contralateral control eye is shown. For ease of
comparison, the data for glaucomatous damage are the same as shown
in Figure 3. In contrast to the spontaneous glaucoma, NMDA-mediated
RGC death is not dependent on BAX, as evident by the complete lack of
protection from death in Bax
 /  mice. As for the spontaneous glaucoma,
RGC death induced by controlled optic nerve crush was completely
dependent on BAX and prevented in both Bax
+/  and Bax
 /  mice.
Overall, the effects of BAX in the face of spontaneous glaucoma and
controlled crush were remarkably similar.
DOI: 10.1371/journal.pgen.0010004.g006
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Bax in Glaucoma Susceptibilityelevated intraocular glutamate levels [59]. The elevated
glutamate levels are proposed to cause excessive stimulation
of glutamate receptors (NMDA type), leading to increased
intracellular calcium levels and RGC death. A different
glaucoma hypothesis involves direct optic nerve injury. In
this hypothesis, high pressure places stress on the optic nerve
as the nerve exits the eye through the lamina cribrosa [60].
Important studies report that the ﬁrst damage to RGCs is
evident in the axon segment near the lamina cribrosa in the
optic nerve head [61,62], so it was suggested that this is the
ﬁrst site of IOP-induced insult (see Quigley [60]). Although it
deﬁnitively shows local axonal dysfunction, the occurrence of
initial damage in this region does not conclusively indicate
that this is the ﬁrst or only site of neuronal insult. Because of
optic nerve head architecture and the stress at the lamina
cribrosa, it is conceivable that the axon segment at the lamina
cribrosa may take substantial resources to maintain, espe-
cially when IOP is elevated. Somal stress may decrease
available resources for axon maintenance and repair. There-
fore, somal stress or damage may contribute to the
abnormalities observed in the optic nerve head. As a group,
Bax
+/  mice had an indistinguishable IOP insult compared to
Bax
+/+ mice, but their RGCs did not undergo pressure-
induced cell death. Importantly, RGC axonal degeneration
was delayed in these Bax
+/  mice. Therefore, our data imply
that shielding the RGC cell bodies has a protective effect
against axon degeneration.
Direct Optic Nerve Damage Resembles Glaucoma
To provide insight to the nature and location of the
damaging insults that occur in glaucoma, we compared the
effects of BAX deﬁciency on RGC death in inherited
glaucoma to RGC death induced by either direct optic nerve
injury or excitotoxicity (all in the genetically uniform DBA/2J
strain). Intraocular NMDA injection was used to model
excitotoxic RGC death, and controlled optic nerve crush
was used to mimic direct optic nerve damage [53,54]. Unlike
the DBA/2J glaucoma, our experiments show that the
excitotoxic insult does not require BAX to induce RGC
death. Although these experiments cannot rule out the
possibility of an intrinsic excitotoxic mechanism, these
results do not support a role of NMDA receptor-mediated
excitotoxicity as a primary cause of glaucomatous RGC death.
Similar to the DBA/2J glaucoma, RGC death following optic
nerve crush requires BAX, and both Bax
+/  and Bax
 /  mice
are profoundly protected. Along with our demonstration of
an axon intrinsic degeneration pathway, these results further
support the hypothesis [60] that direct optic nerve and axon
injury is an important pathogenic component leading to RGC
death in glaucoma.
Bax Can Modulate Neuronal Susceptibility in Glaucoma
Individual patients have different levels of susceptibility to
glaucomatous RGC death [2,63]. Our experiments clearly
identify Bax as an important modulator of neuronal
susceptibility in DBA/2J glaucoma. BAX deﬁciency prevented
RGC death and delayed optic nerve degeneration in both
Bax
+/  and Bax
 /  mice. These results suggest that the use of
BAX inhibitors could potentially be used to delay glaucom-
atous vision loss. In situations where BAX is important,
pharmacologically suppressing BAX activity may signiﬁ-
cantly slow the progression of glaucoma. Since RGCs were
maintained for an extended period after axon degeneration
in Bax
 /  mice, treatments that inhibit BAX pathways may
allow long-term preservation of RGC cell bodies. Such
treatments may allow the RGCs of patients to be stored in
their own retinas until future treatment strategies are
developed that can stimulate axonal growth and restore
vision.
Complete Bax Deficiency Limits IOP Elevation
In addition to implicating BAX as a target for direct
neuroprotective treatments, the lower IOP of Bax
 /  mice
suggests that BAX inhibition may delay or limit IOP
elevation. These results suggest that apoptotic death of cells
affecting aqueous humor drainage contributes to IOP
elevation, at least in secondary glaucomas where the drainage
structures are insulted by pigment and cell debris. In a
previous study assessing neuroprotection by an apoptosis
inhibitor in a rat model of glaucoma, the treated rats had
lower IOP than the other group [25]. Although not a
conclusion of this rat study, the IOP data support a role for
apoptosis in IOP elevation. In humans, cell death has been
speculated to contribute to common forms of glaucoma (due
to loss of drainage structure cells in old individuals and at late
stages of glaucoma [64,65]). However, a primary role for
ocular drainage pathway cell death during IOP elevation is
not clearly established. Importantly, a recent study convinc-
ingly demonstrated endoplasmic reticulum stress and sub-
sequent cell death in primary cultures of drainage pathway
cells expressing human glaucoma mutations [66]. Together
with our ﬁnding that complete BAX deﬁciency delays IOP
elevation in a glaucoma setting, these results strongly support
further investigation of apoptotic pathways and effects of
antiapoptotic drugs on IOP in human glaucoma.
BAX Is a Candidate Human Glaucoma Susceptibility Gene
The profound protection against RGC death and the delay
in axon degeneration in Bax
+/  mice together suggest BAX as
a candidate human glaucoma susceptibility gene. It is
important to note that we considered the possibility that a
closely linked gene that was transferred from the 129/SV
strain (in which the Bax mutation was generated) hitchhiked
into the DBA/2J background along with Bax and explains the
protection in heterozygotes. We conclude that this possibility
is remote on the basis of the following observations. First, the
RGCs of wild-type mice of the parental 129/SV strain are not
protected from optic nerve crush. Bax heterozygosity
protected the animals from both optic nerve crush and
glaucoma in our experiments. This strongly implies that the
parental strain does not have a modiﬁer gene that would
account for the protection we observed. Second, almost all
RGCs were saved in the Bax
+/  mice despite complete axon
degeneration. To our knowledge, only two genes have been
documented that can save the cell when the axon is
destroyed. Substantialo v e r e x p r e s s i o no fBcl2 (a BAX
antagonist) can do this, as can Bax deﬁciency. Thus, it is very
unlikely that there is a similarly potent gene in the congenic
interval, and scanning the ﬂanking chromosome identiﬁes no
obvious candidates.
Complete BAX deﬁciency has developmental consequences
[44] and is unlikely to be common in the human population.
However, human BAX alleles that quantitatively affect the
level of BAX are identiﬁed, and are reported to affect the
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[67–72]. Other factors that control BAX expression could also
be important. Lower levels of BAX are associated with a
worse prognosis for some types of cancer [73]. Our ﬁndings in
Bax
+/  mice support the hypothesis that quantitative varia-
tion in the level of BAX gene product may alter the prognosis
of glaucomatous damage in individuals with high IOP.
Although further studies are needed to assess this possibility,
quantitative variation of BAX activity among human patients
may have a substantial effect on susceptibility and disease
progression. It is possible that lower-activity alleles may result
in slower or less severe damage, whereas high-activity alleles
may be detrimental. Characterization of BAX alleles may have
important predictive value for disease progression.
Materials and Methods
Animals and husbandry. Mice were housed in a 14 h light to 10 h
dark cycle under previously described conditions [74]. The Jackson
Laboratory (Bar Harbor, Maine, United States) pathogen surveil-
lance program regularly screened for pathogens. All experiments
were conducted in accordance with the Association for Research in
Vision and Ophthalmology’s statement on the use of animals in
ophthalmic research and were approved by our institutional animal
care and use committees. Both male and female mice were used. For
each age group and genotype, approximately equal numbers of
males and females were used. A Bax null allele (Bax
tm1Sjk [44]; herein
referred to as Bax
 ) was backcrossed from B6.129X1-Bax
tm1SjK
(obtained from The Jackson Laboratory) onto DBA/2J for more
than 12 generations to generate the congenic strain D2.129X1(B6)-
Bax
tm1Sjk/Sj. Congenic DBA/2J Bax
+/  mice were intercrossed to
produce Bax
+/+, Bax
+/ , and Bax
 /  littermates. All three genotypes
were housed together and analyzed simultaneously. DBA/2J mice
were from our colony (Sj) that was initiated with mice purchased
from The Jackson Laboratory. DBA/1J mice were obtained from The
Jackson Laboratory.
Cell death related assays. Eyes from DBA/2J or control DBA/1J
mice were ﬁxed in 4% paraformaldehyde in 0.1M phosphate buffer
(pH 7.2) for 3 h, transferred to 0.4% paraformaldehyde in 0.1 M
phosphate buffer for 48 h, and inﬁltrated with parafﬁn. Eyes from
two 10- to 11-mo-old DBA/2J mice and two control mice were
sectioned at 5 lm thickness and subjected to a modiﬁed double
labeling protocol that involved in situ end-labeling (equivalent to a
TUNEL assay) of fragmented DNA (using BODIPY ﬂuorophores;
Molecular Probes, Eugene, Oregon, United States) and detection of
condensed chromatin (with the dimeric cyanine dye YOYO-1;
Molecular Probes) as published [75]. Samples were analyzed with a
confocal microscope. Conventional TUNEL assays were performed as
previously reported [13] and conducted on the following numbers of
DBA/2J mice of each age group: 7 mo (six), 8–9 mo (ten), 10–11 mo
(16), 12–13 mo (nine), and 15–18 mo (eight). Five 10- to 12-mo-old
control DBA/1J mice and more than 15 control mice of mixed genetic
background ranging from 10 to 14 mo old were also analyzed. Counts
of TUNEL positive cells were done as previously reported [53].
Brieﬂy, the number of TUNEL-positive RGC layer cells was counted
for eight to 12 sagittal sections from each eye, and average values for
each age group are reported. Eyes used for electron microscopy and
histology were processed as previously described [76], except that
tissue blocks were oriented for en face retinal sectioning through the
ganglion cell layer.
Clinical examination and intraocular pressure measurement. DBA/
2J mice develop a pigmentary form of glaucoma that follows a
characteristic easily detectable clinical course. DBA/2J mice (all
genotypes) used in the spontaneous glaucoma experiments were
assessed with a slit lamp to ensure that the Bax mutation did not alter
the course of the disease. Slit-lamp examination and evaluation
criteria (including pigment dispersion and transillumination) were
previously described [41,42]. Examination of at least 40 mice of each
genotype at 6 and 9 mo of age and at the time of harvest (10.5 or 12
mo) was performed. Additionally, smaller groups of mice (12–20 of
each genotype) were analyzed at other ages between 3 and 12 mo of
age. IOP was recorded [77,78] for mice of each genotype. The number
of mice of each genotype successfully assessed at each age were as
follows. For 4 mo, Bax
+/+ n = 22, Bax
+/  n = 22, Bax
 /  n = 20; for 9
mo, Bax
+/+ n = 21, Bax
+/ n = 25, Bax
 / n = 18; for 10.5 mo, Bax
+/+
n = 50, Bax
+/  n = 54, Bax
 /  n = 52; and for 12 mo, Bax
+/+ n = 42,
Bax
+/ n = 42, Bax
 / n = 37. Student’s t-tests were used for statistical
comparisons.
Optic nerve damage. Optic nerves were dissected, processed,
embedded in plastic, sectioned and stained with paraphenylenedi-
amine (PPD) as previously described [76], except that the staining
time was increased to 35 min and Embed 812 medium was used. PPD
stains all myelin sheaths, but differentially stains the axoplasm of sick
or dying axons darkly. Counts of normal-appearing axons were
performed using established nonbiased counting methods. Prior to
beginning axon counts, the optic nerve was outlined at 1003
magniﬁcation, and its cross-sectional area was automatically calcu-
lated. Magniﬁcation of the same nerve section was increased to
1,0003, and a total of 20 ﬁelds at 1,0003were electronically collected.
The ﬁelds were spaced in a regular fashion across the entire nerve,
taking care to avoid ﬁeld overlap so that the same area was not
counted twice. The 20 collected pictures were stacked on the
computer screen so that only the ﬁnal picture was visible to the
operator. For nerves with a large number of axons (mildly and
moderately affected nerves), a rectangular box that contained a
minimum of 200 axons was then drawn on the twentieth image. For
nerves with severe axon loss, a larger box was drawn so that a
signiﬁcant proportion of the nerve could be counted. The software
program then ‘‘cut’’ a rectangle centred at the same location in all 20
images. Since the operator could only see the top image, this removed
the possibility of unconscious operator bias and made the selection of
axons to be counted random. Axons were counted manually and
marked using the computer. The program tracked the total area
counted and the total axon count for all 20 images. The total counted
area averaged 12.1%, 14.2%, and 20.5% of the total nerve area for
mildly, moderately, and severly affected nerves, respectively. The ﬁnal
count was calculated and expressed as number of axons per optic
nerve. With this approach, the nerves with 95% or more axon loss
were selected for RGC counts by comparing the remaining axon
number to the average for unaffected nerves of the same genotype.
Because of the large number of mice (approximately 50–70 mice of
each genotype at each age), an optic nerve rating scale was used for
the glaucoma progression study (see Figure 5). The indicated damage
levels are readily distinguishable upon inspection of the nerve
without counting. Nevertheless, axon counts were performed on at
least eight randomly selected nerves of each damage grade to provide
quantitative information about these distinct stages of disease (see
below). Two investigators (masked to genotype, age, and the damage
level assigned by the other investigator) assigned a damage level to
each nerve. The two investigators assigned the same grade more than
90% of the time (321 out of 355 nerves). For the nerves on which the
initial two investigators differed, a third (masked) investigator was
utilized. The third investigator’s grade always agreed with one of the
initial grades, and the most common assigned grade was used. The
number of nerves of each genotype assessed at each age were as
follows. For 10.5 mo, Bax
+/+ n = 49, Bax
+/ n = 62, Bax
 / n = 58; for
12 mo, Bax
+/+ n = 71, Bax
+/  n = 50, Bax
 /  n = 65.
The damage levels and typical numbers of normal axons present at
each stage (determined through axon counts by an investigator
masked to damage grade) follow. The representative axon counts
were determined for randomly selected nerves of each grade using
the counting procedure described above. In mildly affected nerves,
there was very mild or no damage, with healthy axons having a clear
axoplasm and intact myelin sheath (average number of axons 6 SEM:
50,504 6 1,988; n = 8). In moderately affected nerves, darkly stained,
degenerating axons were readily detectable, but the vast majority of
axons appeared completely normal (average number of axons 6
SEM: 31,410 6 2,199; n = 8 [79]). In severely affected nerves, there
was extensive axon damage throughout the optic nerve with obvious
axon loss (average number of axons 6 SEM: 7,970 6 2,150; n = 17).
The axon number was signiﬁcantly different between optic nerves of
each damage level (p , 0.001 for all comparisons, t-tests).
Ganglion cell death. Eyes were ﬁxed and retinas were ﬂat-mounted
and Nissl-stained with cresyl violet using a modiﬁcation of the
technique reported by Stone [80]. Retinal ganglion cells make up
approximately 40%–60% of the neurons in the ganglion cell layer of
the mouse retina, and all RGC subtypes cannot be reliably
distinguished from the other resident neuron in the ganglion cell
layer (the displaced amacrine cell) based on cellular morphology
[53,81]. This is especially true during disease, when morphology and
marker expression can change dramatically. Consequently, cell loss
was measured as a function of the change in total cell number
compared to control eyes (strain and genotype matched non-
glaucomatous eyes for the spontaneous glaucoma experiments and
the contralateral nonmanipulated eye for the controlled crush and
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retinal location. Therefore, two 403 ﬁelds were counted in each
retinal quadrant and care was taken to ensure that the ﬁelds were the
same distance from the periphery. For each individual eye, the eight
counts for each retina were averaged. To assess RGC survival in the
spontaneous glaucoma, retinas from eyes with very severely affected
nerves that had fewer than 5% surviving axons were compared to
retinas from unaffected eyes without glaucomatous nerve damage.
RGC number was counted in approximately eight severely affected
eyes and eight unaffected eyes of each genotype, except for
unaffected control Bax
+/  mice (ﬁve eyes) and 18 mo unaffected
Bax
 /  mice (four eyes).
NMDA injections and controlled optic nerve crush. These experi-
ments were performed as described previously [53]. For NMDA
injections, 2 ll of an 80 mM solution of NMDA in balanced saline
solution was injected intravitreally into one eye of each mouse using a
glass micropipet. After 4 d the eyes were harvested and cells counted
as described above. Data were collected from ten Bax
+/+ and eight
Bax
 /  mice. For optic nerve crush, the nerve of one eye was exposed
and clamped approximately 0.5 mm from the globe with self-closing
jeweler’s forceps for 4 s. Eyes were harvested 21 d after surgery and
cells counted. Data were collected from nine Bax
+/+, nine Bax
+/ , and
seven Bax
 / mice. In each paradigm, cell loss was measured relative to
the cell number present in the control eye of each mouse examined.
Supporting Information
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/) accession number for
Bax is 12028.
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